Drs Jeanny B. Aragon-Ching and Srikala Sridhar review key updates in the management of urothelial carcinoma from data presented in 2022.
EP. 1: Incidence and Risk Factors for Urothelial Carcinoma
Jeanny B. Aragon-Ching, MD, FACP, provides an overview of urothelial cancers and the process of diagnosis.
EP. 2: Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma
Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.
EP. 3: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial
Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.
EP. 4: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study
Dr Jeanny B. Aragon-Ching starts a conversation on negative trial data in the high-risk urothelial carcinoma treatment setting for neoadjuvant chemotherapy.
EP. 5: Treatment Options for Frontline Metastatic Urothelial Carcinoma
Drs Aragon-Ching and Sridhar review the available treatment options for patients with frontline metastatic urothelial carcinoma and explain the design of an exciting clinical trial.
EP. 6: Outcomes of the JAVELIN Bladder 100 Trial
Jeanny B. Aragon-Ching, MD, FACP, describes the outcomes of the JAVELIN Bladder 100 study that she presented at ESMO 2022.
EP. 7: Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab
Key opinion leaders discuss the best treatment approaches for urothelial carcinoma after avelumab failure.
EP. 8: Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022
Srikala Sridhar, MD, MSc, FRCPC, and Jeanny B. Aragon-Ching, MD, FACP, wrap up their review of updates in urothelial carcinoma by highlighting exciting data presented at ESMO 2022.
Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma
Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL
Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma